BioNTech, which is first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below typical market rates.
It is also planning to differentiate pricing between countries or regions.
Speaking Tuesday at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer, would reflect the financial risks that its private-sector investors have incurred.
The vaccine has yet to get regulatory approval.
The vaccine on Monday showed to be 90% effective, based on preliminary trial results.
The development is a key milestone in the war against a virus that has killed more than a million people and battered the world's economy.